The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel.
 
Lauren Christine Harshman
Consulting or Advisory Role - Bristol-Myers Squibb; Dendreon; Genentech; Medivation/Astellas; NCCN; Pfizer; PlatformQ Health
Research Funding - Bayer; Medivation/Astellas
 
Kathryn P. Gray
Stock and Other Ownership Interests - dvax
 
Laura Polacek
No Relationships to Disclose
 
Mary-Ellen Taplin
Honoraria - Bayer; Dendreon; Janssen-Ortho; Medivation; Tokai Pharmaceuticals
Consulting or Advisory Role - Bayer; Best Doctors, Inc; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen-Ortho; Medivation; Sanofi; Tokai Pharmaceuticals; UpToDate
Research Funding - Bayer; Genentech; Janssen-Ortho; Medivation
Travel, Accommodations, Expenses - Dendreon; Janssen Oncology; Medivation; Tokai Pharmaceuticals
 
Atish Dipankar Choudhury
No Relationships to Disclose
 
Mark M Pomerantz
No Relationships to Disclose
 
Joaquim Bellmunt
Consulting or Advisory Role - Astellas Pharma; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Channing Yu
No Relationships to Disclose
 
Zijie Sun
No Relationships to Disclose
 
Sandy Srinivas
Consulting or Advisory Role - Genentech/Roche; medivation; pfizer
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; Blend Therapeutics; Metamark Genetics; Placon
Consulting or Advisory Role - Astellas Pharma; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Cristal Therapeutics; Endocyte; Genentech/Roche; GTx; Ipsen; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MorphoSys; MTG Therapeutics; Omnitura; OncoCellMDX; Oncogenex; Pfizer; Sanofi; Sotio; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Expert Testimony - Janssen; Sanofi
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Sanofi
 
Christopher Sweeney
Stock and Other Ownership Interests - BIND Biosciences; Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BIND Biosciences; Genentech/Roche; Janssen Biotech; Sanofi
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Janssen Biotech (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination